[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
November 1982

Thalidomide Treatment of Recurrent Necrotic Giant Mucocutaneous Aphthae and Aphthosis

Author Affiliations

Barcelona, Spain

Arch Dermatol. 1982;118(11):875. doi:10.1001/archderm.1982.01650230003002

To the Editor.—  In the May 1979 Archives (115:636-637), we reported our experience with thalidomide in the treatment of recurrent necrotic giant mucocutaneous aphthae and aphthosis (RNGA) involving six patients. Little other experience with this treatment has been described.1 We have treated 18 patients with RNGA and Behçet's disease with a follow-up evaluation period of six months to four years.In eight of the nine cases of RNGA, the results were excellent, with rapid disappearance of pain, healing of the aphthae, and longer intervals between recurrences. The ninth patient showed less improvement in his condition.The nine patients with Behçet's disease received thalidomide therapy for diverse disease manifestations. The mucocutaneous lesions were well controlled but showed a less dramatic response than those seen in patients with RNGA. In three of the four patients with uveitis, thalidomide therapy had, at least, a partial good effect (shorter duration of outbreaks and

First Page Preview View Large
First page PDF preview
First page PDF preview